The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients
Open accessAbstract
Acute hepatic allograft rejection occurs in approximately 50% to 60% of the patients undergoing liver transplantation. In this study, we compared the rate of acute rejection in liver transplant recipients randomized in a double-blind comparative study to treatment with mycophenolate mofetil (MMF) or azathioprine (AZA), both in combination with cyclosporine and corticosteroids. Five hundred sixty-five primary liver transplant recipients were randomly assigned to treatment with MMF, 1 g twice daily intravenously followed by 1.5 g twice daily orally (n = 278), or AZA, 1.0 to 2.0 mg/kg/d intravenously followed by oral administration (n = 287), in combination with cyclosporine and corticosteroids. Patients were followed up for at least 1 year, and efficacy analysis was based on intent-to-treat methods. Acute rejection was defined according to the Banff histological criteria. The two study groups were balanced for demographic and clinical baseline characteristics. The incidence of acute rejection or graft loss was 47.7% in the AZA patients and 38.5% in the MMF patients (P < .03). The incidence of biopsy-proven and treated rejection censoring for graft loss was 40.0% in the AZA group versus 31.0% in the MMF group (P < .06). Steroid-resistant rejection requiring treatment with either OKT3 or antithymocyte globulin occurred in 8.2% of AZA patients versus 3.8% in MMF patients (P < .02). Patient and graft survival rates at 1 year posttransplantation were 85.4% in the AZA group and 85.3% in the MMF group (P = not significant). MMF was superior to AZA in preventing acute rejection in the first 6 months posttransplantation. MMF and AZA were equivalent in preventing graft loss at 1 year, and the safety profiles between the two immunosuppressive agents were similar.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Banff Schema for Grading Liver Allograft Rejection: An International Consensus Document
Demetris, A. J., Batts, K. P., Dhillon, A. P., Ferrell, L., Fung, J., Geller, S. A., Hart, J., Hayry, P., Hofmann, W. J., Hubscher, S., et al. (1997) · Hepatology · doi:10.1002/hep.510250328 · Cited by 1,272
Self-citationMayer, A. D., Dmitrewski, J., Squifflet, J.-P., Besse, T., Grabensee, B., Klein, B., Eigler, F. W., Heemann, U., Pichlmayr, R., Behrend, M., et al. (1997) · Transplantation · doi:10.1097/00007890-199708150-00012 · Cited by 724
(1994) · The Lancet · doi:10.1016/s0140-6736(94)91766-3 · Cited by 656
A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1
Kobashigawa, J., Miller, L., Renlund, D., Mentzer, R., Alderman, E., Bourge, R., Costanzo, M., Eisen, H., Dureau, G., Ratkovec, R., et al. (1998) · Transplantation · doi:10.1097/00007890-199808270-00016 · Cited by 615
Self-citationAcute hepatic allograft rejection: Incidence, risk factors, and impact on outcome †
Wiesner, R. H., Demetris, J. A., Belle, S. H., Seaberg, E. C., Lake, J. R., Zetterman, R. K., Everhart, J., & Detre, K. M. (1998) · Hepatology · doi:10.1002/hep.510280306 · Cited by 495
Self-citationMathew, T. H. (1998) · Transplantation · doi:10.1097/00007890-199806150-00007 · Cited by 391
Immunosuppressive and other Effects of Mycophenolic Acid and an Ester Prodrug, Mycophenolate Mofetil
Allison, A. C., & Eugui, E. M. (1993) · Immunological Reviews · doi:10.1111/j.1600-065x.1993.tb00652.x · Cited by 384
Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)
Allison, A. C., & Eugui, E. M. (1996) · Clinical Transplantation · doi:10.1111/j.1399-0012.1996.tb00651.x · Cited by 376
A LONG-TERM COMPARISON OF TACROLIMUS (FK506) VERSUS CYCLOSPORINE IN LIVER TRANSPLANTATION1
Wiesner, R. H. (1998) · Transplantation · doi:10.1097/00007890-199808270-00014 · Cited by 214
Self-citationCharlton, M., & Seaberg, E. (1999) · PubMed · doi:10.1053/jtls005s00107 · Cited by 180
Allograft rejection after liver transplantation for autoimmune liver diseases
Hayashi, M., Keeffe, E. B., Krams, S. M., Martinez, O. M., Ojogho, O. N., So, S. K., García, G., Imperial, J. C., & Esquivel, C. O. (1998) · Liver Transplantation and Surgery · doi:10.1002/lt.500040313 · Cited by 99
Stegall, M. D., Simon, M., Wachs, M. E., Chan, L., Nolan, C., & Kam, I. (1997) · Transplantation · doi:10.1097/00007890-199712270-00011 · Cited by 90
Fisher, R. A., Ham, J. M., Marcos, A., Shiffman, M. L., Luketic, V. A., KIMBALL, P. M., Sanyal, A. J., Wolfe, L. G., Chodorov, A., & Posner, M. P. (1998) · Transplantation · doi:10.1097/00007890-199812270-00008 · Cited by 86
Mor, E., Solomon, H. S., Gibbs, J. F., Holman, M. J., Goldstein, R. M., Husberg, B. S., Gonwa, T. A., & Klintmalm, G. B. (1992) · Seminars in Liver Disease · doi:10.1055/s-2007-1007374 · Cited by 72
Self-citationIs acute rejection deleterious to long-term allograft function?
Dousset, B. E., Conti, F., Cherruau, B., Louvel, A., Soubrane, O., Houssin, D. P., & Calmus, Y. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80163-3 · Cited by 65
Statistical methodology in the pharmaceutical sciences
(1991) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(91)90474-k · Cited by 64
Mycophenolate mofetil added to immunosuppression after liver transplantation - first results
Klupp, J., Bechstein, W. O., Platz, K. P., Keck, H., Lemmens, H. P., Knoop, M., Langrehr, J. M., Neuhaus, R., Pratschke, J., & Neuhaus, P. (1997) · Transplant International · doi:10.1007/s001470050046 · Cited by 52
Self-citationUnderlying Disease as a Predictor for Rejection After Liver Transplantation
Berlakovich, G. A. (1998) · Archives of Surgery · doi:10.1001/archsurg.133.2.167 · Cited by 30
Cited by
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
Taylor, A. L., Watson, C. J. E., & Bradley, J. A. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.03.012 · Cited by 445
Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation
van Gelder, T., Meur, Y. L., Shaw, L. M., Oellerich, M., DeNofrio, D., Holt, C., Holt, D. W., Kaplan, B., Kuypers, D., Meiser, B., et al. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000199358.80013.bd · Cited by 331
Self-citationBudde, K., Curtis, J., Knoll, G., Chan, L., Neumayer, H.-H., Seifu, Y., & Hall, M. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00321.x · Cited by 261
Nelson, J., Alvey, N., Bowman, L., Schulte, J., Segovia, M. C., McDermott, J., Te, H. S., Kapila, N., Levine, D. J., Gottlieb, R. L., et al. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2716 · Cited by 130
Metadata
- Authors
- Wiesner, R., Rabkin, J., Klintmalm, G., McDiarmid, S., Langnas, A., Punch, J., McMaster, P., Kalayoglu, M., Levy, G., Freeman, R., Bismuth, H., Neuhaus, P., Mamelok, R., & Wang, W.
- Venue
- Liver Transplantation
- Published
- 2001-05
- Volume
- 7
- Issue
- 5
- Pages
- 442-450
- ISSN
- 1527-6465 (ISSN-L)
- OpenAlex
- W2152627520
- Cited by
- 278
- References
- 22
- FWCI
- 17.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.